All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Amgen Inc. has joined a long list of pharma companies eager to capitalize on Micromet's BiTE antibody platform, which showed unusual promise in recent Phase II studies. The agreement tallies up to $976 million including an up-front payment of €10 million (US$14 million), plus milestones, royalties and development funding.